Brief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
03/06/2026 12:26
BRIEF-Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms June 3 (Reuters) - Tenaya Therapeutics Inc TNYA.O:
TENAYA THERAPEUTICS ANNOUNCES INTERIM DATA FROM MYPEAK™-1 SHOWING TREATMENT OF MYBPC3-ASSOCIATED HCM WITH TN-201 GENE THERAPY RESULTED IN CONSISTENT SIGNS OF CARDIAC REMODELING AND REDUCTIONS IN SYMPTOMS
TENAYA THERAPEUTICS - ALL EVALUABLE PATIENTS SHOW IMPROVEMENTS IN MYBPC3-ASSOCIATED HCM AFTER TN-201 TREATMENT
TENAYA THERAPEUTICS - COHORT 1 BENEFITS SUSTAINED UP TO TWO YEARS; COHORT 2 SHOWS EARLIER IMPROVEMENT
TENAYA THERAPEUTICS - TN-201 WELL TOLERATED WITH NO NEW SAFETY EVENTS REPORTED
Source text: ID:nGNX7M2k8w
Further company coverage: TNYA.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027